SEC Form 4 · accession 0001491519-19-000001
AMERICAN BIO MEDICA CORP · ABMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Chaim Davis
Director
Period of report
Jan 23, 2019
Accepted (ET)
Jan 25, 2019 · 2:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000896747
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF2 | Jan 23, 2019 | A | 38,993 | $0.08 | A | 132,536 | D | |
| Common SharesF3,F4,F5,F6 | Jan 23, 2019 | P | 500,000 | $0.10 | A | 2,449,915 | I | By Revach Fund, LP |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Statutory Stock Option | $0.18 | Apr 26, 2013 | J | 50,000 | A | Apr 26, 2014 | Apr 26, 2023 | Common Shares | 50,000 | 50,000 | D |
Explanation of responses
- F138,993 shares of restricted stock were issued to Davis as compensation for his attendance at a meeting of the Company's Board of Directors held in January 2019. This stock issuance is in accordance with the director compensation structure approved by the Company's Board of Directors on March 22, 2018 (as indicated in the Company's Proxy Statement filed with the Commission on April 20, 2018).
- F2The volume weighted average price of the Company's common shares for the 10 days preceding the issuance was $0.0833 per share.
- F3These restricted shares of common stock were issued in connection with a private placement of up to 2,000,000 units of common stock as disclosed in a Current Report on Form 8-K filed with the Commission on December 24, 2018. Due to a technical delay, the actual issuance of the shares was not affected until January 25, 2019.
- F4The restricted common shares were issued in connection with a private placement completed on December 24, 2018. The Revach Fund, LP was one of the accredited investors who participated in the private placement. 500,000 units were purchased at $0.10 per share; resulting in a total purchase price of $50,000. Davis is a managing member of Revach Group, LLC which operates as the general partner for the Revach Fund,LP. Davis serves as the Chairman of the Board of the Company.
- F5The price per unit in the private placement was $0.10 per share.
- F6The common shares are in the name of Revach Fund, LP. The reporting person (Davis) is a managing member of Revach Group, LLC which operates as the general partner for the Revach Fund, LP.
- F7This non-statutory stock option was previously reported on a Form 3 filed by Davis on April 19, 2018.This stock option is being re-stated on this Form 4. It is not a new award.